The VC that built its name on Algolia and Qonto just made its first big preventive health investment — TFN

• The VC firm behind Algolia, Qonto and Stripe has never led a preventive health deal until now, backing Paris-based Lucis with a $20M Series A

• Singular’s bet signals a deliberate move into health data as the next infrastructure category, following the same pattern that made it an early conviction investor in SaaS and fintech

• Lucis has 10,000 users, 1M+ biomarker tests run, and 75% of users improving key health markers within six months, without medication

Singular built its reputation on infrastructure and fintech, the firm’s founding partners, Jeremy Uzan and Raffi Kamber, cut their teeth backing Algolia, Qonto, and co-investing in Stripe at Alven before spinning out their own firm, which has raised over €625M across two funds. Their pattern is consistent: find a category where data compounds into a structural advantage, and back the team building the layer that everyone else will eventually depend on. This week, for the first time at scale in preventive health, they applied that same logic to human biology.

Now, Singular has led a $20 million Series A into Lucis, a Paris-based preventive health platform founded in 2025 by Maxime Berthelot and Baptiste Debever. General Catalyst and Y Combinator also participated, alongside angels including early investors in Runna (since acquired by Strava). The round brings Lucis’s total funding to $28 million, the bulk raised in roughly five months, following an $8.5M seed in December 2025.